Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [Hematologic Malignancy]

Conclusion
First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable.

Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Amadori, Suciu, Selleslag, Aversa, Gaidano, Musso, Annino, Venditti, Voso, Mazzone, Magro, De Fabritiis, Muus, Alimena, Mancini, Hagemeijer, Paoloni, Vignetti, Fazi, Meert, Ramadan, Willemze, de Witte, Baron Tags: Chemotherapy Hematologic Malignancy Source Type: research